Major Barriers against Renin–Angiotensin–Aldosterone System Blocker Use in Chronic Kidney Disease Stages 3–5 in Clinical Practice: A Safety Concern?

REFERENCES

• Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164:659–663.
   PubMed Web of Science ®Google Scholar
• Fogo AB. Mechanisms of progression of chronic kidney disease. Pediatr Nephrol. 2007;22:2011–2022.
   PubMed Web of Science ®Google Scholar
• Orth SR, Stockmann A, Conradt C, . Smoking as a risk factor for end stage renal failure in men with primary renal disease. Kidney Int. 1998;54:926–931.
   PubMed Web of Science ®Google Scholar
• Hovind P, Rossing P, Tarnow L, Toft H, Parving J, Parving HH. Remission of nephrotic-range albuminuria in type 1 diabetic patients. Diabetes Care. 2001;24:1972–1977.
   PubMed Web of Science ®Google Scholar
• Atkins RC, Briganti EM, Lesis JB, . Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis. 2005;45: 281–287.
   PubMed Web of Science ®Google Scholar
• Peterson JC, Adler S, Burkart JM. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med. 1995;123: 754–762.
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. The collaborative study group. N Engl J Med. 1993;329: 1456–1462.
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, Collaborative Study Group. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860.
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, RENAAL Study Investigators. Effect of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869.
   PubMed Web of Science ®Google Scholar
• Parving HH, Lehnert H, Brochner Mortensen J, Gomis R, Andersen S, Arner P. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345: 870–878.
   PubMed Web of Science ®Google Scholar
• Viberti G, Wheeldon NM. MicroAlbuminuria Reduction with VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure independent effect. Circulation. 2002;106: 672–678.
   PubMed Web of Science ®Google Scholar
• Patel A, MacMahon S, Chalmers J, ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet. 2007;370:829–840.
   PubMed Web of Science ®Google Scholar
• Wright JTJR, Bakris G, Greene T, . Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. J Am Med Assoc. 2002;288:2421–2431.
   PubMed Web of Science ®Google Scholar
• Maschio G, Alberti D, Janin G, The Angiotensin Converting Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Effect of the angiotensin converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med. 1996;334:939–945.
   PubMed Web of Science ®Google Scholar
• The GISEN Study Group. Randomized placebo controlled trial of the effect of ramipril on decline on GFR and risk of terminal renal failure in proteinuric, non diabetic nephropathy. The GISEN Group. Lancet. 1997;349:1857–1863.
   PubMedGoogle Scholar
• Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43:S1–290.
   PubMedGoogle Scholar
• Chobanian AV, Bakris GL, Black HR, . The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. J Am Med Assoc. 2003;289:2560–2572.
   PubMed Web of Science ®Google Scholar
• Winkelmayer WC, Fischer MA, Schneeweiss S, Wang PS, Levin R, Avorn J. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes. Am J Kidney Dis. 2005;46:1080–1087.
   PubMedGoogle Scholar
• Philipneri MD, Rocca Rey LA, Schnitzler MA, . Delivery patterns of recommended chronic kidney disease care in clinical practice: Administrative claims-based analysis and systematic literature review. Clin Exp Nephrol. 2008;12:41–52.
   PubMed Web of Science ®Google Scholar
• Bailie GR, Eisele G, Liu L, . Patterns of medication use in the RRI-CKD study: Focus on medications with cardiovascular effects. Nephrol Dial Transplant. 2005;20:1110–1115.
   PubMed Web of Science ®Google Scholar
• Tonelli M, Gill J, Pandeya S, Bohm C, Levin A, Kiberd BA. Barriers to blood pressure control and angiotensin enzyme inhibitor use in Canadian patients with chronic renal insufficiency. Nephrol Dial Transplant. 2002;17:1426–1433.
   PubMedGoogle Scholar
• Hou FF, Zhang X, Zhang GH, . Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006;354:131–140.
   PubMed Web of Science ®Google Scholar
• Hebert LA. Optimizing ACEI inhibitor therapy for chronic kidney disease. N Engl J Med. 2006;354:189–191.
   PubMed Web of Science ®Google Scholar
• Peralta CA, Hicks LS, Chertow GM, . Control of hypertension in adults with chronic kidney disease in the United States. Hypertension. 2005;45:1119–1124.
   PubMedGoogle Scholar